Avidity Biosciences, Inc. (NASDAQ:RNA / RNAM) Reschedules Special Stockholder Meeting Ahead of Atrium Therapeutics Spin-Off and Novartis Acquisition

Avidity Biosciences, Inc. (formerly NASDAQ: RNA, temporarily RNAM) is a clinical-stage biopharmaceutical company focused on developing a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™) for serious diseases, including rare genetic cardiomyopathies and neuromuscular disorders. On February 23, 2026, Avidity announced it would convene its special stockholder meeting as scheduled and immediately adjourn it without conducting business. The meeting reconvened on February 26, 2026, ...